EWM
ECYT

Elite Wealth Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Elite Wealth Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-48
Closed -$1K – 740
2013
Q4 		$1K Buy
+48
New +$530 ﹤0.01% 842

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Elite Wealth Management's ECYT Position: Q1 2014 in Review

Elite Wealth Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2014, closing a stake of 48 shares — an estimated $1K sold.

Elite Wealth Management first reported a position in ECYT in Q4 2013 and held it in 1 quarter. The position peaked at $1K in Q4 2013. 121 funds tracked by Wall St. Rank hold ECYT as of Q1 2014.

  • Elite Wealth Management reported no remaining Endocyte, Inc. Common Stock position as of Q1 2014 after selling out during the quarter.
  • Elite Wealth Management sold 48 Endocyte, Inc. Common Stock shares in Q1 2014, an estimated $1K.
  • Elite Wealth Management first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 1 quarter.
  • Elite Wealth Management's Endocyte, Inc. Common Stock position peaked at $1K in Q4 2013.
  • 121 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2014.

Based on Elite Wealth Management's 13F filing for Q1 2014, filed 23 Nov 2016.